-- Fady Ibraham Malik, Executive Vice President, Research & Development, on April 07, 2026, sold 4,500 shares in Cytokinetics (CYTK) for $292,985. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1061983/000106198326000034/xslF345X05/form4.xml